134 related articles for article (PubMed ID: 35985457)
1. The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial.
Brand DH; Brüningk SC; Wilkins A; Naismith O; Gao A; Syndikus I; Dearnaley DP; van As N; Hall E; Gulliford S; Tree AC;
Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):327-336. PubMed ID: 35985457
[TBL] [Abstract][Full Text] [Related]
2. Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.
Brand DH; Brüningk SC; Wilkins A; Fernandez K; Naismith O; Gao A; Syndikus I; Dearnaley DP; Tree AC; van As N; Hall E; Gulliford S;
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):596-608. PubMed ID: 33412260
[TBL] [Abstract][Full Text] [Related]
3. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
4. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.
Devisetty K; Zorn KC; Katz MH; Jani AB; Liauw SL
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1060-5. PubMed ID: 20045267
[TBL] [Abstract][Full Text] [Related]
5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
7. Prediction of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer.
D'Avino V; Palma G; Liuzzi R; Conson M; Doria F; Salvatore M; Pacelli R; Cella L
Radiat Oncol; 2015 Apr; 10():80. PubMed ID: 25890376
[TBL] [Abstract][Full Text] [Related]
8. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
9. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.
Hoffman KE; Voong KR; Pugh TJ; Skinner H; Levy LB; Takiar V; Choi S; Du W; Frank SJ; Johnson J; Kanke J; Kudchadker RJ; Lee AK; Mahmood U; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1074-84. PubMed ID: 24661661
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
11. Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review.
Neerhut T; Grills R; Lynch R; Preece PD; McLeod K
Urol Oncol; 2024 Jun; 42(6):165-174. PubMed ID: 38503591
[TBL] [Abstract][Full Text] [Related]
12. Estimation of α/β for late rectal toxicity based on RTOG 94-06.
Tucker SL; Thames HD; Michalski JM; Bosch WR; Mohan R; Winter K; Cox JD; Purdy JA; Dong L
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):600-5. PubMed ID: 21377288
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
14. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.
Norkus D; Karklelyte A; Engels B; Versmessen H; Griskevicius R; De Ridder M; Storme G; Aleknavicius E; Janulionis E; Valuckas KP
Radiat Oncol; 2013 Sep; 8():206. PubMed ID: 24007322
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
17. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer.
Marzi S; Saracino B; Petrongari MG; Arcangeli S; Gomellini S; Arcangeli G; Benassi M; Landoni V
J Exp Clin Cancer Res; 2009 Aug; 28(1):117. PubMed ID: 19689825
[TBL] [Abstract][Full Text] [Related]
18. Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?
Kountouri M; Zilli T; Rouzaud M; Dubouloz A; Linero D; Escudé L; Jorcano S; Miralbell R
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):272-9. PubMed ID: 26853336
[TBL] [Abstract][Full Text] [Related]
19. Prediction of toxicities of prostate cancer radiotherapy.
Hostova B; Matula P; Dubinsky P
Neoplasma; 2016; 63(1):163-8. PubMed ID: 26639247
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
